Equity Profile

PODD

Insulet Corporation

Health CareHealth Care Equipment$10.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insulet Corporation is a healthcare company specializing in innovative insulin delivery systems for people with diabetes. With a market cap of $10 billion, it operates in the health care equipment sector, focusing on improving patient outcomes through technology.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1 2026, Insulet reported an EPS of $1.42, surpassing expectations by 24.78%. However, the stock fell 9.70% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Continued investment in product innovation.
Expansion into new markets.
Focus on improving customer support and education.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Insulet's upcoming earnings, given its history of beating EPS estimates. However, the recent stock drop raises concerns about future performance.

Bull Case

If Insulet continues to show strong EPS growth and expands its market share, it could lead to a significant increase in stock value.

Bear Case

Conversely, if the company fails to meet revenue expectations or faces increased competition, it could result in a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

A strong EPS figure could reinforce investor confidence and support a bullish outlook for the stock.

How is Insulet addressing competition in the insulin delivery market?

Insights into competitive strategies will be crucial for understanding the company's future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insulet's ability to maintain its growth trajectory despite competitive pressures. The company's innovative product pipeline and strong customer loyalty could drive better-than-expected results.

Supporting Evidence

Insulet has consistently beaten EPS estimates in the past, suggesting a trend of strong performance.

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

Management's focus on innovation and market expansion could yield positive surprises.

Key Risk

If the company reports an EPS below $1.10, it could significantly undermine the growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical for assessing Insulet's growth trajectory and market position.

Bull Confirmed If

An EPS of $1.50 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.10 would suggest significant challenges and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests a potential stock increase of around +1.90%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement.

Miss

A miss on EPS could lead to a decline of approximately -1.09%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on sales.
2Any changes in guidance regarding market expansion efforts.
3Insights into customer feedback and satisfaction levels.
4Discussion on competitive landscape and how Insulet plans to differentiate.
5Details on cost management and operational efficiencies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1 2026, Insulet reported an EPS of $1.42, surpassing expectations by 24.78%. However, the stock fell 9.70% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Continued investment in product innovation.
Expansion into new markets.
Focus on improving customer support and education.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Insulet's upcoming earnings, given its history of beating EPS estimates. However, the recent stock drop raises concerns about future performance.

Bull Case

If Insulet continues to show strong EPS growth and expands its market share, it could lead to a significant increase in stock value.

Bear Case

Conversely, if the company fails to meet revenue expectations or faces increased competition, it could result in a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

A strong EPS figure could reinforce investor confidence and support a bullish outlook for the stock.

How is Insulet addressing competition in the insulin delivery market?

Insights into competitive strategies will be crucial for understanding the company's future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

Insulet has consistently beaten EPS estimates in the past, suggesting a trend of strong performance.

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

Management's focus on innovation and market expansion could yield positive surprises.

Key Risk

If the company reports an EPS below $1.10, it could significantly undermine the growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical for assessing Insulet's growth trajectory and market position.

Bull Confirmed If

An EPS of $1.50 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.10 would suggest significant challenges and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests a potential stock increase of around +1.90%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement.

Miss

A miss on EPS could lead to a decline of approximately -1.09%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on sales.
2Any changes in guidance regarding market expansion efforts.
3Insights into customer feedback and satisfaction levels.
4Discussion on competitive landscape and how Insulet plans to differentiate.
5Details on cost management and operational efficiencies.